|
|
Phase III Randomized Study of Cetuximab With Versus Without Brivanib Alaninate in Patients With Metastatic Colorectal Carcinoma Previously Treated With Combination Chemotherapy
Alternate Title Basic Trial Information Objectives Entry Criteria Expected Enrollment Outcomes Outline Trial Contact Information Registry Information
Alternate Title
Cetuximab With or Without Brivanib in Treating Patients With Metastatic Colorectal Cancer
Basic Trial Information
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Biomarker/Laboratory analysis, Treatment
|
|
|
|
Active
|
|
|
|
18 and over
|
|
|
|
Other
|
|
|
|
CAN-NCIC-CO20 CO20, CAN-NCIC-CA182009, NCT00640471
|
|
|
Objectives Primary - To compare the overall survival of patients with previously treated metastatic colorectal
carcinoma treated with brivanib alaninate in combination with cetuximab versus placebo in
combination with cetuximab.
Secondary - To compare the progression-free survival of these patients.
- To compare the objective response rate and duration of response in these patients.
- To compare the quality of life of these patients.
- To compare the health utilities of these patients.
- To conduct a comparative economic evaluation of these patients.
- To evaluate the safety profile of this regimen in these patients.
- To explore an association between FGF-2, K-RAS mutations, amphiregulin (AREG) and
epiregulin (EREG) as determined from paraffin embedded tumor specimens and the potential
for clinical benefit from the addition of brivanib alaninate or placebo to cetuximab in terms
of overall survival, progression-free survival and objective response rate compared to cetuximab
alone.
- To explore an association with changes of Collagen IV in the blood and the potential for clinical
benefit from the addition of brivanib alaninate to cetuximab in terms of overall survival,
progression-free survival and objective response rate compared to cetuximab alone.
- To establish a comprehensive tumor bank linked to a clinical database for the further study of
molecular markers in colorectal cancer.
Entry Criteria Disease Characteristics:
- Histologically confirmed primary colorectal cancer
- Must have received a prior thymidylate synthase inhibitor (e.g., fluorouracil, capecitabine, raltitrexed,
or tegafur-uracil) for adjuvant and/or metastatic disease
- Thymidylate synthase inhibitor may have been given in
combination with oxaliplatin or irinotecan hydrochloride
- Must meet one of the following criteria:
- Received and failed* an irinotecan hydrochloride-containing regimen (i.e., single-agent or in combination)
for treatment of metastatic disease
- Relapsed within 6 months of completion of an irinotecan
hydrochloride-containing adjuvant therapy
- Has documented unsuitability** for an irinotecan hydrochloride-containing regimen
[Note: *Failure is defined as either progression of disease or intolerance to the irinotecan-containing regimen,
where intolerance is defined as discontinuation due to any of the following: severe allergic reaction
or delayed recovery from toxicity preventing retreatment] [Note: **Documented unsuitability for irinotecan includes known hypersensitivity to irinotecan, abnormal
glucuronidation of bilirubin, Gilbert’s syndrome, previous pelvic/abdominal irradiation, or elderly
with comorbid conditions]
- Must meet one of the following:
- Received and failed* an oxaliplatin-containing regimen (i.e. single-agent or in combination) for
treatment of metastatic disease
- Relapsed within 6 months of completion of an oxaliplatin
containing adjuvant therapy
- Has documented unsuitability** for an oxaliplatin-containing
regimen
[Note: *Failure is defined as either progression of disease or intolerance to the oxaliplatin-containing
regimen, where intolerance is defined as discontinuation due to any of the following: severe allergic
reaction, persistent severe neurotoxicity or delayed recovery from toxicity preventing retreatment] [Note: **Documented unsuitability for oxaliplatin includes known hypersensitivity to oxaliplatin or other
platinum compounds, pre-existing renal impairment, or Grade 2 or greater neurosensory neuropathy]
- Measurable or evaluable disease
- Patient must consent to provision of, and investigator(s) must confirm access to and agree to submit
at the request of the NCIC CTG Central Tumor Bank, a representative formalin fixed paraffin block
of tumour tissue
- Patient must consent to provision of a sample of blood
- No symptomatic CNS metastases
- Patients with signs or symptoms suggestive
of brain metastasis are not eligible unless brain metastases are ruled out by CT or MRI scans
Prior/Concurrent Therapy:
- See Disease Characteristics
- Adequately recovered from recent surgery, chemotherapy and/or radiation therapy
- At least 4 weeks
must have elapsed from major surgery, prior chemotherapy, prior treatment with an investigational
agent or prior radiation therapy
- No prior cetuximab or other therapy* with targets the EGFR pathway (e.g., erlotinib hydrochloride, gefitinib hydrochloride, panitumumab)
- May have received a single prior regimen which targets the VEGFR pathway (e.g., bevacizumab , vatalanib,
AZD2171, sorafenib tosylate, sunitinib malate, or others)
- No prior murine monoclonal antibody therapy (e.g., edrecolomab)
- No other concurrent chemotherapy
- No other concurrent therapies targeting the EGFR pathway (e.g.,
erlotinib, gefitinib, panitumumab, or others) or other therapies
targeting the VEGFR pathway (e.g., bevacizumab , vatalanib,
AZD2171, sorafenib tosylate, sunitinib malate, or others)
- Concurrent antihypertensive therapies allowed
- Concurrent aspirin allowed
- No other concurrent noncytotoxic experimental agents
Patient Characteristics:
Inclusion criteria: - ECOG performance status 0-2
- Absolute granulocyte count ≥ 1.5 x 109/L
- Platelet count ≥ 75 x 109/L
- Hemoglobin ≥ 80 g/L
- Total bilirubin ≤ 1.5 times upper limit of normal (ULN) (2.0 times ULN with documented liver metastases)
- ALT and AST ≤ 2.5 times ULN (5.0 times ULN with documented liver metastases)
- Serum creatinine ≤ 1.5 times ULN or creatinine clearance > 50 mL/min
- Magnesium > 0.5 mmol/L (1.2 mg/dL)
- LVEF > 45% by ECHO or MUGA scan
- No proteinuria ≥ 2+ on dipstick or ≥ 1 g on 24 hour urine collection
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception prior to, during, and for 12 weeks after completion of study treatment
- Able (i.e., sufficiently fluent) and willing to complete the quality of life (EORTC QLQ-C30
and Skindex-16) and health utilities questionnaires (HUI3) in either English or French
Exclusion criteria: - A history of other malignancies, except: adequately treated nonmelanoma skin cancer, curatively
treated in situ cancer of the cervix, or other solid tumors curatively treated with no evidence of
disease for ≥ 5 years
- Any active disease condition which would render the protocol treatment dangerous or impair the
ability of the patient to receive protocol therapy
- Any condition (e.g., psychological, geographical, etc.) that does not permit compliance with the
protocol
- Uncontrolled or significant cardiovascular disease including any of the following:
- Myocardial infarction within 12 months
- Uncontrolled angina within 6 months
- Clinically significant congestive heart failure
- Stroke, transient ischemic attack, or other ischemic event within 12 months
- Severe cardiac valve dysfunction
- Uncontrolled hypertension (consistent elevation of systolic BP > 150 and diastolic BP > 100 mmHg)
- History of a thromboembolic event in the last 6 months despite being treated with anticoagulation
- Patients are eligible if they have experienced a thromboembolic event greater than 6
months previously and have initiated and are stable on anticoagulation or if they have previously
initiated and are stable on anticoagulation for prevention of thromboembolic events
- Severe restrictive lung disease or radiological pulmonary findings of “interstitial lung disease” on the
baseline chest x-ray which, in the opinion of the investigator, represents significant pathology
- Serious non-healing wounds, ulcers, or bone fractures
- History of allergy to brivanib (alaninate or related drug class
Expected Enrollment 750Outcomes Primary Outcome(s)Overall survival
Secondary Outcome(s)Progression-free survival Objective response rate Duration of response Quality of life (using EORTC QLQ-C30 and Skindex-16 Dermatology Survey) Health utilities (using HUI3 Health Utilities Index) Economic evaluation Safety profile Molecular markers
Outline This is a multicenter study. Patients are stratified according to participating center and ECOG performance status (0-1 vs 2). Patients are randomized to 1 of 2 arms. - Arm I: Patients receive oral brivanib alaninate once daily and cetuximab IV over 60-120 minutes once weekly.
- Arm II: Patients receive oral placebo once daily and cetuximab IV over 60-120 minutes once weekly.
In both arms, treatment continues in the absence of disease progression or unacceptable toxicity. Tumor tissue and blood samples are collected for correlative studies. Samples are analyzed for biomarker levels (Collagen IV, FGF-2, and epiregulin, amphiregulin, and K-ras mutations status) and correlation with response. After completion of study treatment, patients are followed at 4 weeks and then every 8 weeks thereafter.
Trial Contact Information
Trial Lead Organizations NCIC-Clinical Trials Group | | | Lillian Siu, MD, FRCPC, Protocol chair | | | | Trial Sites
|
|
|
|
Canada |
|
Ontario |
|
|
Ottawa |
|
| | | | Ottawa Hospital Regional Cancer Centre - General Campus |
| | Derek Jonker | |
|
|
Toronto |
|
| | Princess Margaret Hospital |
| | Lillian Siu | |
|
Quebec |
|
|
Quebec City |
|
| | | Centre Hospitalier Universitaire de Quebec |
| | Felix Couture | |
|
Saskatchewan |
|
|
Regina |
|
| | | Allan Blair Cancer Centre at Pasqua Hospital |
| | Muhammad Salim | |
|
Registry Information | | Official Title | | A Phase III Randomized Study of Brivanib Alaninate (BMS-582664) in Combination with Cetuximab (Erbitux®) Versus Placebo in Combination with Cetuximab (Erbitux®) in Patients Previously Treated with Combination Chemotherapy for Metastatic Colorectal Carcinoma | | Trial Start Date | | 2008-05-01 (estimated) | | Trial Completion Date | | 2010-12-01 (estimated) | | Registered in ClinicalTrials.gov | | NCT00640471 | | Date Submitted to PDQ | | 2008-03-17 | | Information Last Verified | | 2008-05-20 |
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. Back to Top |
|